The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases
- PMID: 32016032
- PMCID: PMC6976477
- DOI: 10.21037/atm.2019.10.31
The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases
Conflict of interest statement
Conflicts of Interest: MS Ahluwalia: Receipt of grants/research supports: Astrazeneca, Abbvie, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Merck; Receipt of honoraria or consultation fees: Elsevier, Wiley, Astrazeneca, Abvvie, VBI Vaccines, Flatiron, Varian Medical Systems, Prime Education, Bayer, karyopharm, Tocagen, Forma therapeutics; Stock shareholder: Doctible, Mimivax. The other author has no conflicts of interest to declare.
Comment on
-
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13. J Clin Oncol. 2019. PMID: 31194611 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources